Skip to content

Goodwill at other companies

Amgen logo
AmgenAMGN
$18.67B+0.2%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$4.7M0.0%
Opko Health logo
Opko HealthOPK
$482.27M+1.2%
XER
Xeris Biopharma Holdings, Inc.XERS
$22.86M0.0%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$44M-0.9%
LQD
Liquidia CorporationLQDA
$3.9M0.0%

Other financials

Income statement

See full
Revenue$58.8M+10.3%
Gross profit$54.2M+10.8%
Operating income$11.9M-7.0%
Net income$8.7M-24.4%
EPS (diluted)$0.44-30.2%

Balance sheet

See full
Cash & equivalents$24.5M-46.6%
Total debt$68.4M+5,079%
Total equity$399.9M+2,054%
Total assets$504.6M+187%

Cash flow

See full
Operating cash flow$2.7M+405%
CapEx$73.0K
Free cash flow-$22.0M

Valuation

See full
Market cap$684.39M+102%
Enterprise value$728.29M+148%
P/E1.9×-7.2×
P/S2.3×+0.6×

Profitability

See full
Gross margin93.4%+3.7pp
Operating margin41.6%+19.9pp
Net margin121.5%+103pp
FCF margin-61.7%

Returns & leverage

See full
Return on equity174.1%
Debt / equity0.2×+0.1×
Current ratio2.6×+0.4×

Where this comes from

Reported directly by Rigel Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IntangibleAssetsNetIncludingGoodwill.

The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rigel Pharmaceuticals's goodwill.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rigel Pharmaceuticals's goodwill?
Rigel Pharmaceuticals (RIGL) reported goodwill of $24.16M in Q1 2026.
How has Rigel Pharmaceuticals's goodwill changed year-over-year?
Rigel Pharmaceuticals's goodwill decreased by 8.9% year-over-year, from $26.51M to $24.16M.
What is the long-term trend for Rigel Pharmaceuticals's goodwill?
Over 3 years (2022 to 2025), Rigel Pharmaceuticals's goodwill has grown at a 18.3% compound annual growth rate (CAGR), from $14.95M to $24.75M.
What does goodwill mean?
The excess of acquisition cost over the fair value of net identifiable assets acquired — representing brand value, customer relationships, and synergies from past M&A.